Rimokh R, Berger F, Delsol G, Digonnet I, Rouault JP, Tigaud JD, et al. Detection of the chromosomal translocation t (11; 14) by polymerase chain reaction in mantle cell lymphomas. 1994.

Beà S, Amador V. Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. 2017;19:1–10.

Article  Google Scholar 

Maddocks K. Update on mantle cell lymphoma. Blood J Am Soc Hematol. 2018;132(16):1647–56.

CAS  Google Scholar 

Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023;7(11):2287–96.

Article  CAS  PubMed  Google Scholar 

Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2017;181(5):703–6.

Article  PubMed  Google Scholar 

Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13:1–18.

Article  Google Scholar 

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–67.

Article  CAS  PubMed  Google Scholar 

Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine KinaseZanubrutinib for relapsed/refractory MCL. Clin Cancer Res. 2020;26(16):4216–24.

Article  CAS  PubMed  Google Scholar 

Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901.

Article  CAS  PubMed  Google Scholar 

Martin P. Ibrutinib–a new standard treatment for relapsed mantle cell lymphoma? Lancet. 2016;387(10020):728–9.

Article  PubMed  Google Scholar 

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.

Article  CAS  PubMed  Google Scholar 

Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200(2):137–49.

Article  CAS  PubMed  Google Scholar 

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study. Hematol Oncol. 2017;35(4):528–35.

Article  CAS  PubMed  Google Scholar 

Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zain R, Vihinen M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Correction: Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2019;9(11):1629.

Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29(4):895–900.

Article  CAS  PubMed  Google Scholar 

Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood. 2022;139(5):666–77.

Article  CAS  PubMed  Google Scholar 

Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.

Article  CAS  PubMed  PubMed Central  Google Scholar 

George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel). 2020;12(5):1328.

Article  CAS  PubMed  Google Scholar 

Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62–72.

CAS  PubMed  Google Scholar 

Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, et al. MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S394–5.

Article  CAS  PubMed  Google Scholar 

Wang ML, Shah NN, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood. 2022;140(Supplement 1):9368–72.

Article  Google Scholar 

Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, et al. MCL-135 BRUIN MCL-321, a phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK Inhibitor in patients with previously treated, btk inhibitor naive mantle cell lymphoma (trial in progress). Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S395–6.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9(16):13023–35.

Article  PubMed  PubMed Central  Google Scholar 

Burkart M, Karmali R. Relapsed/refractory mantle cell lymphoma: beyond BTK inhibitors. J Pers Med. 2022;12(3):376.

Article  PubMed  PubMed Central  Google Scholar 

Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. J Pers Med. 2021;11(8):764.

Article  PubMed  PubMed Central  Google Scholar 

Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019;133(9):952–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry. 2018;57(26):3564–75.

Article  CAS  PubMed  Google Scholar 

Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2020;30(3):126877.

Article  CAS  PubMed  Google Scholar 

Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia. 2019;33(8):2105–10.

Article  PubMed  Google Scholar 

Lim YS, Yoo SM, Patil V, Kim HW, Kim HH, Suh B, et al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023;7(1):92–105.

Article  CAS  PubMed  Google Scholar 

Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:491.

Article  Google Scholar 

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92.

Article  CAS  PubMed  Google Scholar 

Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, et al. Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial. J Clin Oncol. 2016;34(15_suppl):7570.

Article  Google Scholar 

Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Gine E, et al. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status. Haematologica. 2017;102(11):e447–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180–90.

Article  PubMed  PubMed Central  Google Scholar